Genzyme Convenes 13th European Fabry Disease Roundtable

Thu Apr 18, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

Genzyme Convenes 13th European Fabry Disease Roundtable

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that the 13th European Fabry Disease Roundtable will take place April 19 and 20 in Madrid, Spain. The Roundtable is a scientific meeting sponsored by Genzyme that brings together more than 200 participants from around the world, including physicians, academics, researchers and patient organization representatives to discuss current clinical care for patients with Fabry disease and the future direction of disease management. This year’s Roundtable is chaired by Franco Cecchi, MD, Professor of Cardiology, University of Florence, Italy.

The theme of this year’s meeting is “Improving Specialized Care in Fabry Disease,” with special focus on multidisciplinary care, and on new data and insights regarding the diagnosis and management of patients with Fabry disease.

“By providing a platform for both treating physicians and physicians who are newer to Fabry disease, we have the opportunity to connect as a community to learn from each other, sharing knowledge about the diagnostic process and the clinical management of Fabry disease, with the goal to optimize patient care,” said Dr. Cecchi. “I believe this will be an inspiring scientific event where we will exchange and discuss clinical and scientific data that can be applied in clinical practice.”

Among the topics for discussion:

  • Multidisciplinary care management in Fabry disease
  • Suspecting and diagnosing Fabry disease
  • New data regarding Genotypes and Phenotypes
  • Update on Fabry Disease Registry data
  • Trends in research
  • Biomarker identification

“The Fabry Disease Roundtable is a tremendous opportunity to bring together thought leaders from around the world to exchange ideas, debate and further increase our understanding of this disease,” said Genzyme’s Head of Rare Diseases Rogerio Vivaldi, MD. “As we continue to better understand the optimal way to care for patients who live with Fabry, there will be particular focus on how adopting a multidisciplinary approach can improve treatment outcomes.”

About Fabry Disease

Fabry disease is caused by a genetic deficiency of an enzyme known as alpha-galactosidase A or alpha-GAL, and is characterized by excessive accumulation of the lipid GL-3 in various organs and tissues. Signs and symptoms begin in childhood and lead to progressive life-threatening renal, cardiac, and cerebrovascular complications. As a result, patients with Fabry disease typically have a shortened life span, and children must often cope with significant pain and disability. Fabry disease is a rare inherited disease linked to the X chromosome and is estimated to affect roughly 1 in 117,000 people in the general population.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. This goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Genzyme® is the registered trademark of Genzyme Corporation. All rights reserved.

Sanofi Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Media Contact:
Genzyme
Lori Gorski, 617-768-9344
Lori.gorski@genzyme.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.